Every Form 4 that Cadrenal Therapeutics, Inc. (CVKD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.
Cadrenal Therapeutics Chairman and CEO Quang Pham, a more than 10% owner, reported an open-market sale of 7,400 shares of common stock on June 29, 2026 at a weighted average price of $3.03 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025.
Following the sale, Pham directly holds 98,589 shares of Cadrenal common stock. He also has indirect ownership of 200,000 shares held by The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power and his child is the sole beneficiary.
Cadrenal Therapeutics, Inc. director and Chairman, CEO and Interim CFO Quang X. Pham reported open-market sales of the company’s common stock. He sold 2,127 shares at $3.00 per share and 9,029 shares at a weighted average of $3.05 per share in late June 2026.
The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham held 105,989 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics director and CEO Quang Pham reported open-market stock sales under a pre-set trading plan. He sold 9,167 shares of common stock on June 22, 2026 at a weighted average price of $3.55 per share and 2,277 shares on June 23, 2026 at a weighted average price of $3.20 per share, totaling 11,444 shares sold. These transactions were executed pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025. After the sales, he held 117,145 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
Cadrenal Therapeutics Chairman and CEO Quang X. Pham reported open-market sales of 4,126 shares of Common Stock at weighted average prices around $3.16–$3.18 per share. The sales on June 16–17, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2025.
After these transactions, Pham holds 128,589 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power. The reported sales represent a small portion of his overall reported holdings and do not involve any derivative exercises.
Cadrenal Therapeutics director and CEO Quang X Pham reported open-market sales of company stock. He sold a total of 18,124 shares of Cadrenal Therapeutics, Inc. common stock in three transactions on June 11, 12 and 15, 2026, at weighted average prices of $4.12, $3.94 and $3.58 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham holds 132,715 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. Chairman, CEO and Interim CFO Quang X Pham reported open-market sales of a total of 22,385 shares of common stock over three days. Shares were sold at weighted average prices of about $4.38 on June 8, $4.06 on June 9, and $4.21 on June 10, in transactions described as carried out under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these sales, Pham holds 150,839 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X. Pham reported open-market sales of a total of 8,285 shares of common stock on June 3–5, 2026 at weighted average prices of $4.26, $4.41 and $4.42 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the transactions, he holds 173,224 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang Pham reported small open-market sales of company common stock. He sold 303 shares on May 29, 2026 at a weighted average price of $5.01 per share and 349 shares on June 2, 2026 at a weighted average price of $4.46 per share, totaling 652 shares. The sales were executed under a pre-arranged Rule 10b5-1 trading arrangement. After these transactions, Pham holds 181,509 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X Pham reported open-market sales of 12,763 shares of common stock. The sales occurred on May 11, May 12, and May 28, 2026, at reported weighted average prices of $5.76, $5.28, and $4.93 per share.
The footnotes state these transactions were made under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the latest sale, Pham holds 182,161 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power. The filing also corrects an earlier understatement of indirect holdings on a prior Form 4.
Cadrenal Therapeutics CEO and Chairman Quang Pham reported an open-market sale of 1,165 shares of Common Stock on May 22, 2026 at a weighted average price of $5.69 per share, executed as an "S" code transaction.
The sale was made pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025, meaning it was pre-arranged. After the sale, Pham directly owns 194,924 shares of Cadrenal Therapeutics common stock and indirectly holds 20,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power.
Cadrenal Therapeutics (CVKD) reported insider transactions by its Chief Financial Officer, Matthew K. Szot. He sold 1,800 shares of common stock on October 24, 2025, and 1,800 shares on October 27, 2025, each at $13.99 per share, coded as open‑market sales (S).
The filing states these trades were executed under a Rule 10b5-1 trading plan adopted on May 9, 2025. Following the reported sales, the officer directly beneficially owns 9,933 shares.
Cadrenal Therapeutics (CVKD): CEO/Chairman Quang Pham reported open‑market sales under a Rule 10b5‑1 plan. On 10/24/2025, he sold 1,129 shares of common stock at a weighted average price of $14.03, with trades ranging from $13.99 to $14.10. On 10/27/2025, he sold 1,315 shares at a weighted average price of $13.99, with trades ranging from $13.99 to $14.00. The trading arrangement was adopted on May 9, 2025.
Following these transactions, direct beneficial ownership was 197,404 shares after the first sale and 196,089 shares after the second. He also holds 200,000 shares indirectly through The PVBQ Living Trust, for which he serves as trustee with sole voting and disposition power.
Cadrenal Therapeutics (CVKD) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO sold 1,693 shares of common stock at $13.99, and on 10/13/2025, sold 1,800 shares at $14.07, in each case under a Rule 10b5-1 trading arrangement. Following these sales, the CFO directly beneficially owned 13,533 shares.
Cadrenal Therapeutics (CVKD) reported insider transactions by CEO, Chairman and Director Quang Pham, who is also a 10% owner. Under a Rule 10b5-1 trading arrangement, he sold 1,800 shares on 10/09/2025 at a weighted average price of $14.02 and 1,800 shares on 10/13/2025 at a weighted average price of $14.15. Each sale comprised multiple trades within disclosed price ranges.
Following these transactions, Mr. Pham directly beneficially owns 198,533 shares. He also indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, for which he is trustee with sole voting and disposition power.
Cadrenal Therapeutics (CVKD) Chief Financial Officer Matthew K. Szot reported a sale of common stock under a prearranged trading plan. The Form 4 shows a disposition of 107 shares at $13.99 per share on 10/06/2025, leaving the reporting person with 17,026 shares beneficially owned. The filing indicates the sale was made pursuant to a Rule 10b5-1 arrangement and is signed by the reporting person.
Cadrenal Therapeutics, Inc. (CVKD) director, CEO and chairman Quang Pham reported a planned sale of 500 shares of common stock executed on 10/02/2025 under a Rule 10b5-1 trading arrangement at prices ranging from $14.04 to $14.27, with a weighted average price of $14.13. Following the transaction, Mr. Pham directly owns 202,133 shares and indirectly holds 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Cadrenal Therapeutics insider Form 4 summary: Director, CEO and Chairman Quang Pham reported pre-arranged sales of common stock under a Rule 10b5-1 trading plan. On 09/29/2025 he sold 419 shares at a weighted average price of $14.01, and on 10/01/2025 he sold 881 shares at a weighted average price of $14.01. Following these transactions Mr. Pham directly beneficially owned 202,633 shares. He also has indirect beneficial ownership of 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power.
Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on two dates. On 09/24/2025 he sold 1,500 shares at a weighted average price of $13.9953, and on 09/25/2025 he sold 10,900 shares at a weighted average price of $14.0534, for a total of 12,400 shares sold. After these transactions the reporting person beneficially owned 18,933 shares, down from 29,833 shares following the first sale. The Form 4 is signed by the reporting person on 09/26/2025 and includes explanatory notes that the reported sales occurred in multiple transactions within the stated price ranges.
Cadrenal Therapeutics insider Form 4 summary: Quang Pham, CEO, Chairman, director and reported 10% owner of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on 09/24/2025 and 09/25/2025. On 09/24/2025 he sold 2,581 shares at $13.99 each, leaving 210,723 shares directly owned after that transaction. On 09/25/2025 he sold 6,790 shares in multiple transactions with a weighted average price of $14.09, leaving 203,933 shares directly owned after those sales. Mr. Pham also has indirect ownership of 200,000 shares held by The PVBQ Living Trust; he is Trustee with sole voting and disposition power and the trust’s sole beneficiary is his child. The filing was signed by an attorney-in-fact on 09/26/2025.